Skip to content

In the BioHarmony Drug Report Database

Aminolevulinic acid

Ameluz, Gleolan, Levulan, Gliolan (aminolevulinic acid) is a small molecule pharmaceutical. Aminolevulinic acid was first approved as Ameluz on 1999-12-03. It is used to treat actinic keratosis in the USA. It has been approved in Europe to treat actinic keratosis, basal cell carcinoma, and glioma. Levulan kerastick's patent is valid until 2038-01-12 (FDA).
Trade Name Ameluz, Gliolan
Common Name Aminolevulinic acid
Indication actinic keratosis, basal cell carcinoma, glioma
Drug Class
Aminolevulinic acid
Get full access now